Harnessing the Therapeutic Potential of Mitochondrial DNA
CohBar is a clinical-stage biotechnology company exploiting the power of the mitochondria and its encoded peptides to develop potential breakthrough therapeutics targeting chronic and age-related diseases. While extensive work has been conducted on the nuclear genome, we are the first to discover potential therapeutics sourced from the mitochondrial genome.
We developed our Mito+ platform to enable us to identify and develop peptides that we believe have great promise as potential human therapeutics. One of the key early insights that led to the development of CohBar’s novel platform was the recognition that certain mitochondrially encoded peptides produce effects that are not limited to local regulation within the mitochondria and may have important roles to play in critical systemic biological pathways quite distinct from what has traditionally been thought of as mitochondrial function. CohBar is using this novel approach to develop analogs of these natural peptides to treat a variety of serious systemic conditions, with a focus on diseases involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH). As analogs of naturally occurring peptides, we expect our product candidates to have better safety and tolerability profiles compared to other drug development approaches focused on non-natural starting points.
As the first company to mine the mitochondrial genome for therapeutically relevant peptides, we have established a robust and growing IP portfolio with 15 issued patents and over 65 patent filings.
View PipelineServing Patients with Unmet Medical Needs
Our unique technology offers a differentiated approach to treating a wide range diseases.
View Patient ResourcesIdiopathic Pulmonary Fibrosis (IPF)
IPF is a chronic, progressive, debilitating, and usually fatal interstitial lung disease that affects approximately 100,000 people in the U.S. This orphan disease results in fibrotic scarring of the lungs. Current treatment options are limited and poorly tolerated.
Learn More About IPFNonalcoholic Steatohepatitis (NASH)
An emerging epidemic, NASH is projected to affect 27 million U.S. adults by 2030. NASH is a progressive liver disease that is one of the leading causes of cirrhosis in the United States. It is associated with a variety of metabolic disorders, including diabetes, obesity, and lipid abnormalities. There is currently no approved treatment.
Learn More About NASHObesity
Obesity impacts more than 40% of U.S. adults and is a major risk factor for a variety of other serious diseases, including heart disease, stroke, type 2 diabetes, NASH and certain types of cancer.
Learn More About ObesityAcute Respiratory Distress Syndrome (ARDS)
ARDS occurs when fluid builds up in the tiny, elastic air sacs, or alveoli, of the lungs, resulting in poor blood oxygenation. ARDS is typically a complication of some other primary condition, such as pneumonia, sepsis, or trauma. Current treatment is primarily supportive, along with treatment of the underlying infection or trigger. Mortality rates are high and many patients that survive experience lasting lung damage.
Learn More About ARDS
A Powerhouse Leadership Team
Our leadership team is comprised of experienced scientists, doctors, and biotech executives.